Mara Bacchiani

Mara Bacchiani

Auto-generated profile, based on publicly available information

Mara Bacchiani

Department of Urology, University of Florence, Florence, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MBMara Bacchiani
Mara Bacchiani
VSVincenzo Salamone
Vincenzo Salamone
EMEleana Massaro
Eleana Massaro
ASAlessandro Sandulli
Alessandro Sandulli
RMRiccardo Mariottini
Riccardo Mariottini
OGon behalf of European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group
on behalf of European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group
Introduction: Lymph node (LN) involvement is a crucial determinant of prognosis for patients with bladder cancer, and an accurate staging is of utmost importance to better identify timely and appropriate therapeutic strategies. To improve the accuracy of LN detection, as an alternative to traditional methods such as CT or MRI, 18F-FDG PET/CT has been increasingly used. 18F-FDG PET/CT is also used in post-treatment restaging after neoadjuvant chemotherapy. The aim of this narrative literature review is to provide an overview of the current evidence on the use of 18F-FDG PET/CT in the diagnosis, staging, and restaging of bladder cancer, with a particular focus on its sensitivity and specificity for the detection of LN metastasis. We aim to provide clinicians with a better understanding of 18F-FDG PET/CT’s potential benefits and limitations in clinical practice. Materials and Methods: We designed a narrative review starting from a wide search in the PubMed/MEDLINE and Embase databases, selecting full-text English articles that have examined the sensibility and specificity of PET/CT for nodal staging or restaging after neoadjuvant therapy in patients with bladder cancer. The extracted data were analyzed and synthesized using a narrative synthesis approach. The results are presented in a tabular format, with a summary of the main findings of each study. Results: Twenty-three studies met the inclusion criteria: fourteen studies evaluated 18F-FDG PET/CT for nodal staging, six studies examined its accuracy for restaging after neoadjuvant therapy, and three studies evaluated both applications. To date, the use of F-18 FDG PET/TC for detection of LN metastasis in bladder cancer is controversial and uncertain: some studies showed low accuracy rates, but over the years other studies have reported evidence of high sensitivity and specificity. Conclusions: 18F-FDG PET/CT provides important incremental staging and restaging information that can potentially influence clinical management in MIBC patients. Standardization and development of a scoring system are necessary for its wider adoption. Well-designed randomized controlled trials in larger populations are necessary to provide consistent recommendations and consolidate the role of 18F-FDG PET/CT in the management of bladder cancer patients.


7 May 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
FMFabrizio Di Maida
Fabrizio Di Maida
AGAntonio Andrea Grosso
Antonio Andrea Grosso
LLLuca Lambertini
Luca Lambertini
DPDaniele Paganelli
Daniele Paganelli
AMAndrea Marzocco
Andrea Marzocco
AMAndrea Minervini
Andrea Minervini

18 November 2025 in La radiologia medica
Verified
Journal Article
Open access
PDF file
AVAntonio Vizzuso
Antonio Vizzuso
MBMaria Vittoria Bazzocchi
Maria Vittoria Bazzocchi
MBMara Bacchiani
Mara Bacchiani
GMGiorgia Musacchia
Giorgia Musacchia
ASAntonio Spina
Antonio Spina
Matteo RenzulliMatteo Renzulli
Matteo Renzulli
Purpose: To evaluate the clinical efficacy and safety of prostatic artery embolization (PAE) using glue (n-butyl cyanoacrylate, NBCA) in patients with benign prostatic hyperplasia (BPH) presenting with lower urinary tract symptoms (LUTS) due to obstruction or chronic urinary retention managed with an indwelling catheter (IUC). Material and Methods: A total of 101 patients (median age 79 years) were included, of whom 67 had LUTS and 34 had an IUC. All were treated with PAE with glue between 2021 and 2024. Clinical success was defined as either a ≥ 25% reduction in the International Prostate Symptom Score (IPSS) and a ≥ 3-point improvement in the quality of life (QoL) score or stable catheter removal. Results: Technical success was achieved in 100% of cases, with bilateral embolization in 93% of patients. Among symptomatic patients, clinical success was observed in 92.5%, with a reduction in IPSS from 25.3 ± 8.1 to 15.3 ± 7.8 and in QoL from 4.5 ± 1.1 to 2.3 ± 1.4 at 36 months ( p < 0.001). Mean prostate volume decreased by 37.6%. In patients with an IUC, 73.5% resumed spontaneous voiding within an average of 29 days. All complications (13.9%) were minor and managed conservatively. Conclusion: Embolization with acrylic glue is a safe and effective minimally invasive alternative to surgery for BPH, with sustained long-term results. It is particularly suitable for elderly patients with comorbidities or those unfit for surgery presenting with LUTS or chronic urinary retention.